<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6372">
  <stage>Registered</stage>
  <submitdate>26/02/2017</submitdate>
  <approvaldate>26/02/2017</approvaldate>
  <nctid>NCT03087110</nctid>
  <trial_identification>
    <studytitle>Stem Cells in Umbilical Blood Infusion for CP</studytitle>
    <scientifictitle>Safety Study of Sibling Cord Blood Cell Infusion to Children With Cerebral Palsy</scientifictitle>
    <utrn />
    <trialacronym>SCUBI-CP</trialacronym>
    <secondaryid>U1111-1179-9253</secondaryid>
    <secondaryid>HREC/14/RCHM/38; RCH ID 34210</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cerebral Palsy</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Matched sibling donor cord blood cell infusion

Experimental: Cord blood infusion - Matched sibling donor cord blood cell infusion


Other interventions: Matched sibling donor cord blood cell infusion
Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (&gt;1x10^7 cells/kg)

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with abnormal clinical assessment and/or laboratory values - Safety</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary analysis of change in gross motor function - Gross Motor Function Measure (GMFM-66)</outcome>
      <timepoint>Baseline, 3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary analysis of change in gross motor function - Gross Motor Function Measure (GMFM-66)</outcome>
      <timepoint>Baseline, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary analysis of change in fine motor function - Quality of Upper Extremity Skills Test (QUEST)</outcome>
      <timepoint>Baseline, 3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary analysis of change in fine motor function - Quality of Upper Extremity Skills Test (QUEST)</outcome>
      <timepoint>Baseline, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary analysis of change in cognitive function - Age appropriate cognitive testing: Bayley Scales of Infant and Toddler Development (BSID-III), Wechsler Preschool Primary Scale of Intelligence (WPPSI-IV), Wechsler Intelligence Scale for Children (WISC-V). Change from baseline will be compared using z-scores across measures.</outcome>
      <timepoint>Baseline, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary analysis of change in quality of life - Cerebral Palsy Quality of Life (CP-QoL-CHILD)</outcome>
      <timepoint>Baseline, 3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary analysis of change in quality of life - Cerebral Palsy Quality of Life (CP-QoL-CHILD)</outcome>
      <timepoint>Baseline,12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Digital PCR analysis of peripheral blood cellular DNA to determine the fraction of donor DNA in circulation - Chimerism study to detect the longevity of infused cells</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Diagnosis of any type of CP

          2. CP of any severity

          3. A record of sibling CBU in storage at a TGA accredited private cord blood bank

          4. Ability to travel to one of the trial centres

          5. Ability to participate in assessments

          6. Informed consent by parent/guardian</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Year</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. presence of progressive neurological disease

          2. known genetic disorder

          3. known brain dysplasia

          4. immune system disorder or immune deficiency syndrome

          5. infectious disease markers showing up on virology screen

          6. evidence of cord blood unit contamination, or fewer than 10^7 cells/kg body mass

          7. ventilator support

          8. ill health, or if the participant's medical condition does not allow safe travel

          9. previous cell therapy

         10. Botulinum toxin A within 3 months before or after infusion

         11. surgery within 3 months before or after infusion

         12. cannot obtain parent/guardian consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Lady Cilento Children's Hospital - Brisbane</hospital>
    <hospital>The Royal Children's Hospital - Melbourne</hospital>
    <postcode>4101 - Brisbane</postcode>
    <postcode>3052 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Murdoch Childrens Research Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The Royal Children's Hospital Melbourne</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Children's Health Queensland</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Monash Health</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Sydney Children's Hospitals Network</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cerebral Palsy Alliance</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will investigate the safety of single dose intravenous infusion of cord blood
      cells which were cryopreserved after the birth of a brother or sister to a child with
      cerebral palsy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03087110</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dinah Reddihough, MBChB, MD</name>
      <address>Group leader</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>